JCR Pharmaceuticals Co., Ltd. (JP:4552)
:4552
Top Page
JCR Pharmaceuticals Co., Ltd.
(4552)
Select Model
Select Model
Rating:58Neutral
Price Target:
¥575.00
▼(-19.24% Downside)
Action:ReiteratedDate:11/28/25
The overall stock score is primarily influenced by strong technical analysis, indicating bullish momentum. However, significant financial challenges and a negative P/E ratio weigh down the score. The attractive dividend yield provides some support, but the company's financial health needs improvement to sustain long-term growth.
Positive Factors
Specialist in rare diseases & biologics
JCR's specialization in rare-disease therapeutics and biologics creates durable competitive advantages: high technical barriers, specialized regulatory pathways, and pricing/ reimbursement levers. This focus supports sticky revenue streams, partnership interest, and differentiated R&D capability over time.
Negative Factors
Negative operating & free cash flow
Persistent negative operating and free cash flow undermine the firm's ability to self-fund R&D, manufacturing scale-up, or commercialization. Over months this forces reliance on external financing, increasing dilution or interest costs and constraining strategic flexibility for product rollout.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialist in rare diseases & biologics
JCR's specialization in rare-disease therapeutics and biologics creates durable competitive advantages: high technical barriers, specialized regulatory pathways, and pricing/ reimbursement levers. This focus supports sticky revenue streams, partnership interest, and differentiated R&D capability over time.
Read all positive factors
JCR Pharmaceuticals Co., Ltd. (4552) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥68.43B
Dividend Yield2.71%
Average Volume (3M)578.69K
Price to Earnings (P/E)638.6
Beta (1Y)0.90
Revenue Growth7.15%
EPS Growth-454.41%
CountryJP
Employees934
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.27
Shares Outstanding129,686,310
10 Day Avg. Volume668,090
30 Day Avg. Volume578,686
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.27
Price to Sales (P/S)1.81
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥710.00Price Target Upside-0.28% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)11.83
Revenue Forecast (FY)¥38.80B
JCR Pharmaceuticals Co., Ltd. Business Overview & Revenue Model
Company Description
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various ...
How the Company Makes Money
JCR Pharmaceuticals makes money primarily by selling prescription pharmaceuticals and biopharmaceutical products. Its revenue model typically includes: (1) product sales from medicines it commercializes in Japan through distribution to medical ins...
JCR Pharmaceuticals Co., Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.50B | 33.07B | 42.87B | 34.34B | 51.08B | 30.09B |
| Gross Profit | 21.86B | 21.55B | 31.25B | 25.46B | 40.62B | 22.27B |
| EBITDA | -3.69B | -3.47B | 10.73B | 6.97B | 21.88B | 10.16B |
| Net Income | -5.50B | -4.76B | 5.51B | 3.77B | 14.51B | 6.89B |
Balance Sheet | ||||||
| Total Assets | 107.34B | 105.45B | 102.67B | 95.36B | 97.48B | 74.16B |
| Cash, Cash Equivalents and Short-Term Investments | 13.18B | 13.20B | 18.76B | 13.28B | 30.98B | 26.26B |
| Total Debt | 40.10B | 38.28B | 23.43B | 22.92B | 18.16B | 18.16B |
| Total Liabilities | 60.72B | 58.01B | 46.19B | 42.95B | 46.39B | 35.60B |
| Stockholders Equity | 46.26B | 47.04B | 56.18B | 52.16B | 50.88B | 38.38B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -15.37B | 7.79B | -13.15B | -2.04B | 5.56B |
| Operating Cash Flow | 0.00 | -5.49B | 9.31B | -5.50B | 9.29B | 10.34B |
| Investing Cash Flow | 0.00 | -9.87B | -2.69B | -15.00B | -3.25B | -3.29B |
| Financing Cash Flow | 0.00 | 9.74B | -2.03B | 1.95B | -2.18B | 8.30B |
JCR Pharmaceuticals Co., Ltd. Technical Analysis
Negative
712.00
Price Trends
613.67
Negative
652.85
Negative
625.98
Negative
Market Momentum
-15.21
Positive
38.20
Neutral
6.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4552, the sentiment is Negative. The current price of 712 is above the 20-day moving average (MA) of 580.27, above the 50-day MA of 613.67, and above the 200-day MA of 625.98, indicating a bearish trend. The MACD of -15.21 indicates Positive momentum. The RSI at 38.20 is Neutral, neither overbought nor oversold. The STOCH value of 6.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4552.
JCR Pharmaceuticals Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥1.31T | 19.73 | 4.27% | 2.33% | -3.36% | -55.41% | |
58 Neutral | ¥68.43B | 638.63 | ― | 2.71% | 7.15% | -454.41% | |
52 Neutral | ¥137.39B | -8.84 | ― | 2.18% | -0.16% | -802.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥24.49B | -34.16 | ― | ― | -5.65% | -469.19% | |
49 Neutral | ¥11.23B | -8.85 | ― | ― | -42.49% | -2.37% | |
48 Neutral | ¥91.85B | -5.96 | -19.31% | ― | -1.96% | -64.18% |
* Healthcare Sector Average
JP:4552
JCR Pharmaceuticals Co., Ltd.
548.00
134.66
32.58%
JP:4151
Kyowa Kirin Co
2,496.00
379.28
17.92%
JP:4565
Sosei Group
1,011.00
198.00
24.35%
JP:4974
Takara Bio Inc.
1,142.00
361.00
46.22%
JP:7774
Japan Tissue Engineering Co., Ltd.
599.00
149.00
33.11%
JP:7776
CellSeed Inc.
291.00
-244.00
-45.61%
JCR Pharmaceuticals Co., Ltd. Corporate Events
JCR Pharmaceuticals Overhauls Leadership and Structure to Drive Global Biopharma Growth
Feb 26, 2026
JCR Pharmaceuticals has approved a major leadership transition effective April 1, 2026, appointing Toru Ashida as Representative Director and Chairman and Hiroyuki Sonoda as Representative Director, President, and Chief Scientific Officer, while f...
JCR Pharmaceuticals Swings Back to Profit and Lifts Full-Year Outlook
Jan 28, 2026
JCR Pharmaceuticals reported a sharp turnaround in earnings for the nine months ended December 31, 2025, with net sales rising 17.3% year on year to ¥30.35 billion and a swing to profit attributable to owners of parent of ¥1.74 billion f...
JCR Books ¥1.88 Billion Government Subsidy as Extraordinary Income for Q3 FY2025
Jan 28, 2026
JCR Pharmaceuticals has recognized ¥1.882 billion in government subsidy income as extraordinary income in the third quarter of FY2025, following the finalization of a subsidy related to the construction of its Kobe Science Park Center active ...
JCR Pharmaceuticals Issues FY2025 Q3 Results Briefing With Caution on Outlook
Jan 28, 2026
JCR Pharmaceuticals has released materials for its FY2025 third-quarter results briefing, outlining its financial performance and progress in business operations. The company emphasizes that any forecasts or projections in the briefing are subject...
JCR Pharmaceuticals Lifts Sales Outlook but Slashes Profit Forecast on Higher R&D and Costs
Jan 28, 2026
JCR Pharmaceuticals has revised its consolidated forecast for the fiscal year ended March 31, 2026, projecting higher net sales of ¥39.5 billion, up 4.5% from its previous estimate, driven mainly by stronger-than-expected demand for therapies...
JCR Pharmaceuticals Briefs Investors on New Agreement with Italfarmaco
Jan 23, 2026
JCR Pharmaceuticals has held a briefing session regarding its agreement with Italian drugmaker Italfarmaco, signaling a potential strategic collaboration in the pharmaceutical field. While specific deal terms or operational details are not disclos...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.